Influenza A virus (IAV), a promising oncolytic virus modified by reverse genetics and a recombinant influenza virus expressing CTLA4 (RFlu‐CTLA4) antibody, was constructed to treat hepatocarcinoma (HCC) in a subcutaneous H22 mouse model. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.